NCT00692289已完成不适用
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 1,510
- 试验地点
- 1
- 主要终点
- Elements of the investigator questionnaire SF RAND-36 questionnaire
研究概览
简要总结
This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Provision of informed consent
- •Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex
- •Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.
排除标准
- •Allergy to substance of medication
- •Pre-perimenopausal woman
- •Woman not eligible for treatment
结局指标
主要结局
Elements of the investigator questionnaire SF RAND-36 questionnaire
时间窗: Quarterly (plus or minus 3 days )
次要结局
- Investigator Assessment Report(Yearly (plus or minus 1 week ))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Arimidex Observational: Reason for and Effect of Change From TamoxifenBreast CancerNCT00246961AstraZeneca200
已完成
3 期
ATAC - Quality of Life Sub-ProtocolQuality of LifeNCT00784680AstraZeneca308
已完成
不适用
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast CancerAdvanced Breast CancerNCT00562458AstraZeneca200
已完成
3 期
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 YearsBreast CancerNCT00286117AstraZeneca448
已完成
不适用
Greek Study of the Quality of Life in Patients With Psoriasis Treated With AdalimumabPsoriasisNCT01077128AbbVie (prior sponsor, Abbott)500